Capricor Therapeutics (CAPR) is a San Diego-based clinical-stage biotechnology company developing cell and exosome therapies for rare diseases, led by deramiocel, an investigational allogeneic cell therapy for Duchenne muscular dystrophy. Shares changed hands at $8.32 on Thursday, up $0.29, or 3.61%, from the previous session's close of $8.03. The direction is unambiguously higher, but the driver is not a fresh disclosure. No company news, filing, or analyst action appeared before the move; the advance reflects pre-decision positioning into an FDA action date now three days away, layered on a rebound from Wednesday's late-session selloff.
No verified news or fundamental catalyst found in Thursday's flow. The absence is itself informative: with the regulatory calendar fixed, there was nothing new to price other than the passing of time toward Nov. 22. The internals fit a familiar pre-event pattern rather than a new disclosure — a gap higher to $9.12 shortly after the open, a fade back to roughly $8.02 within two hours, and a renewed push into the afternoon, all inside a day range of about 18%. That whipsaw behavior is consistent with speculative two-way hedging around a binary outcome, not with an information shock.
The substance driving sentiment was already public. The FDA reset the Prescription Drug User Fee Act target date for deramiocel to Nov. 22, 2026 after Capricor filed a major amendment built on 24-month HOPE-3 open-label extension data and more than 900 robustness re-analyses, alongside a narrowed proposed indication covering upper-limb function in patients older than nine. HOPE-3 met its primary endpoint with a 1.1-point advantage on the PUL 2.0 measure (p=0.029). Against that sits a July advisory committee vote of 9-3 against the cardiomyopathy evidence — a vote that did not address the upper-limb endpoint, but which has kept approval expectations firmly two-sided.
Because the payoff is binary, small shifts in perceived odds translate into outsized percentage moves. Wednesday illustrated the mechanism: the stock rallied early on news that the White House had withdrawn its nominee to lead the FDA, then surrendered the entire gain and closed down 4.52% on 8.4 million shares. Thursday's bounce partially reverses that markdown rather than establishing a new trend.
Roughly 1.9 million shares had traded by late morning, putting the session on pace to meet or exceed the stock's average volume of about 4 million shares — active, but short of the conviction seen Wednesday. Sector signals were mixed: large-cap biotech edged higher, while the small-cap Russell 2000 proxy fell, meaning Capricor's gain was idiosyncratic rather than a tide-lifting move. Technically, the shares remain far below their 50- and 200-day averages and about 79% under the 52-week high of $40.37, with $7.71 intraday and $7.99 from Wednesday acting as near-term support, and $9.12-$9.49 the immediate ceiling. Market capitalization sits near $500 million.
The scale runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This session earns a 13 out of 100. The verified news component is weak: nothing new was disclosed Thursday, and the only live catalyst is a scheduled regulatory date that has been public since August. The price component is equally muted — at 3.61%, the move was only about 0.65 times the stock's typical absolute daily change of roughly 5.6% over the past 60 sessions. Larger single-session swings occurred 38 times in that window. With neither component strong, the score stays low.
The decisive variable is the FDA's action on the deramiocel BLA, targeted for Nov. 22, with the label's wording — particularly the age cutoff and functional endpoint language — mattering as much as the approval itself. A Rare Pediatric Disease designation could also yield a priority review voucher. Beyond the decision, investors face the distribution dispute with NS Pharma, which heads to arbitration in mid-2027, and a balance sheet carrying $198.5 million in cash after a $42.7 million third-quarter loss and a roughly 10% workforce reduction. Final Phase 1 StealthX vaccine data are expected in the first half of 2027, and the next scheduled financial report is due around March. The principal risk is a complete response letter, which would leave a pre-revenue company burning roughly $45 million a quarter.
Tickeron operates hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions evolve. For readers navigating event-driven volatility like Capricor's, it offers a structured way to see which automated approaches are currently working. Review the page to compare live performance before deciding what fits your process.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on October 29, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The 10-day RSI Indicator for CAPR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In 71 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
CAPR moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.592). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (442.120).
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology